Abstract Library

#4563 Clinical case of a young woman with acromegaly, hyperprolactinemia and pituitary tumour with mixed morphology of adenoma and gangliocytoma

Introduction: Acromegaly is a rare disorder that develops due to persistent hypersecretion of somatotropic hormone in adults after closure of the growth plates. In the majority of cases, the cause is a pituitary adenoma.

Conference:

Presenting Author:

Authors: Markova M, Kirova I, Elenkova A, Robeva R, Zacharieva S,

Keywords: acromegaly, hyperprolactinemia, pituitary adenoma, gangliocytoma,

#4471 Acromegaly and small intestinal neuroendocrine tumours: Association or coincidence?

Introduction: Neuroendocrine tumours of the small intestine (SI-NETs), although rare, are the most prevalent primary neoplasms of this organ. Acromegaly is characterised by excessive secretion of growth hormone (GH), typically due to a pituitary adenoma, but in rare cases, it can result from ectopic secretion of GH-releasing hormone (GHRH) by non-pituitary tumours, particularly NETs of the lung or pancreas.

Conference:

Presenting Author: G. Martins R

Authors: Martins Fernandes A, Silva L, Serranito M, Elvas A, Santos J,

Keywords: neuroendocrine tumour, small intestinal neuroendocrine tumour, acromegaly,

#3490 Effects of radiation therapy for somatotropic pituitary adenomas depending on age

Introduction: Despite the fact that medical therapy is effective in controlling somatotropinomas, radiation therapy (RT) is still offered as a valuable choice as a treatment for pituitary adenomas.

Conference:

Presenting Author:

Authors: Issaeva S, Khalimova Z, Khokimboeva M, Davronova N,

Keywords: radiation therapy, somatotropinomas, age, growth hormone,

#86 Structure of complications in acromegalic patients at a single institute

Introduction: Acromegaly leads to reduced life expectancy, with an increase in the mortality rate. From several retrospective cohort studies, the predominant outcome is serum growth hormone (GH) concentration. Other factors associated with increased mortality include duration of symptoms prior to diagnosis, duration of disease, older age at diagnosis and the presence of cardiovascular disease, diabetes mellitus (DM) and hypertension at diagnosis.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Khyzhnyak O, Mykytyuk M, Karachentsev Y,

Keywords: acromegaly, growth hormone, somatotropinoma, somatomammotropinoma, complications ,

#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy

Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kassem S

Authors: Kassem S, Gross D, Doviner V, Dresner-Pollak R,

Keywords: pituitary carcinoma, peptide receptor radionuclide therapy, acromegaly,